A way around a problem
21 December, 2005 by Iain ScottBiotechnology has provided a solution to the problem of how to get science to the market without compromising research, writes editor-in-chief Iain Scott.
Facing up to commercial reality
21 December, 2005 by Ruth BeranThe research community is becoming more sophisticated in the way they approach intellectual property and industry partnerships. Ruth Beran looks at how technology transfer has changed, where it is going and the challenges it faces.
INTERVIEW: Sir Gus's big picture view
15 December, 2005 by Ruth BeranRuth Beran asked Sir Gustav Nossal about Australia's latest institute -- which just happens to bear his name.
Glaxo is using delaying tactics: Biota CEO
14 December, 2005 by Ruth BeranThe CEO of Melbourne company Biota Holdings (ASX:BTA), Peter Cook, believes GlaxoSmithKline is using delaying tactics in the current court case before the Victorian courts, in which Biota is suing GSK for up to AUD$430 million.
Alchemia raises $5m in share purchase plan
14 December, 2005 by Helen SchullerBrisbane biopharma Alchemia (ASX:ACL) has successfully raised AUD$5 million, closing its share purchase plan heavily oversubscribed. Earlier this month the company raised $14.6 million through a share placement.
BrainZ lists at premium
14 December, 2005 by Helen SchullerAuckland-based BrainZ (ASX:BZI), which develops monitors for the detection of brain injury, listed on the ASX today at AUD$0.54, four cents above its issue price of $0.50.
Cochlear announces earnings upgrade
14 December, 2005 by Ruth BeranBionic ear specialist Cochlear (ASX:COH) has announced an upgrade of its guidance on core earnings for the 2005-06 financial year to AUD$80 million.
NZ-based VC invests in Cleveland Biosensors
14 December, 2005 by Helen SchullerBrisbane start-up Cleveland Biosensors has attracted investment capital from New Zealand-based VC BioPacific Ventures.
Alexanders Securities to strengthen biotech stake
14 December, 2005 by Ruth BeranAlexanders Securities (ASX:ALE), a financial services firm previously focused on investments in shares and providing venture capital to companies, is re-positioning itself as a consumer healthcare and biotechnology company.
Sunshine Heart raises $3.3m
13 December, 2005 by Helen SchullerSunshine Heart (ASX:SHC) has raised AUD$3.3 million through a private placement to fund the development of its C-Pulse heart assist device.
Biotech IPOs continue to test market
13 December, 2005 by Helen SchullerWhile many companies are preparing to shut down for the festive season, parts of the Australian biotech sector show no signs of getting into holiday mode.
CEO sees GTG leading the way for Aust biotech
13 December, 2005 by Graeme O'NeillA major court victory against US firm Applera will put Genetic Technologies (ASX:GTG) in a leadership position in Australian biotechnology, the firm's CEO has predicted.
Phylogica, McComb Foundation collaborate on burns treatment
09 December, 2005 by Ruth BeranPerth-based Phylogica (ASX:PYC) and the McComb Foundation are jointly developing a potential new drug to speed up the healing process and reduce the scarring caused by burns.
Premier Bionics raises $1.25m for Israeli trauma simulator
09 December, 2005 by Helen SchullerPremier Bionics (ASX:PBI) has raised AUD$1.25 million in a placement to provide capital to accelerate the development of a mass trauma simulator in Israel.
BTF earns fast growth kudos
09 December, 2005 by Helen SchullerPrivate Sydney-based biotech BTF has achieved 101 per cent revenue growth over the last three years, earning itself a place in the 2005 Deloitte Technology Fast 50 awards.
